Want to join the conversation?
$TGNA's 4Q15 non-GAAP expenses were down over 4%. EBITDA was strong & EBITDA margin of 38% was comparable to 4Q14, despite the absence of substantial higher margin political spending. $TGNA announced a $75MM increase in the share repurchase program bringing it up to $825MM, which will be used over the original three-year term ending June. 2018.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.